Nanoparticles for Cancer Immunotherapy: Innovations and Challenges

Area of Science:

• Oncology
• Immunology
• Nanotechnology
• Biomedical Engineering

Background:

• Cancer treatment is evolving with immunotherapies that leverage the host immune system against tumors.
• Current immunotherapies show promise but face challenges like limited patient response, off-target effects, immune evasion, and poor pharmacokinetics.

Purpose of the Study:

• To review recent advancements in targeted drug delivery systems for cancer immunotherapy.
• To explore the application of nanoparticles, liposomes, exosomes, and Wharton's jelly-derived macrovesicles in enhancing immune cell function and overcoming therapeutic resistance.
• To identify and discuss current challenges in biocompatibility, scalability, and regulatory aspects of these delivery systems.

Main Methods:

• Literature review focusing on targeted drug delivery systems in cancer immunotherapy.
• Analysis of nanoparticles, liposomes, exosomes, and Wharton's jelly-derived macrovesicles as drug delivery vehicles.
• Characterization of challenges and proposed solutions for engineering and regulatory hurdles.

Main Results:

• Targeted delivery systems show potential to improve the efficacy and safety of cancer immunotherapy.
• Nanoparticles, liposomes, exosomes, and macrovesicles can enhance immune cell activity and overcome resistance mechanisms.
• Biocompatibility, scalability, and regulatory approval remain significant challenges for clinical translation.

Conclusions:

• Integrating advanced drug delivery systems with cancer immunotherapy offers a promising strategy for more effective and safer cancer treatment.
• Addressing current challenges is crucial for the successful clinical implementation of these novel therapeutic approaches.
• This review bridges drug delivery innovation and immunotherapy advancements, providing insights for future cancer therapy development.